Position in CELC
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$6,707,188
New position
Shares Held
64,110
first reported quarter
Ownership
0.131%
of shares outstanding
% of Portfolio
1.09%
of 13F equity value
Holder Rank
#78
of 273 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 0%
Shared 100%
None 0%
Position in Biotechnology
Healthcare · as of Jun 30, 2026Tetragon Partners GP Ltd holds $170,564,204 across 22 Biotechnology names. CELC ranks #16 (3.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AUTL |
Autolus Therapeutics plc
|
9,500,000 | $15,200,000 | |
| 2 | DFTX |
Definium Therapeutics, Inc.
|
286,990 | $13,500,009 | |
| 3 | MBX |
MBX Biosciences, Inc.
|
203,543 | $11,235,573 | |
| 4 | CLDX |
Celldex Therapeutics, Inc.
|
290,441 | $10,807,309 | |
| 5 | RLAY |
Relay Therapeutics, Inc.
|
570,311 | $10,670,518 | |
| 6 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
130,484 | $10,635,750 | |
| 7 | PHVS |
Pharvaris N.V.
|
295,627 | $10,222,781 | |
| 8 | IMVT |
Immunovant, Inc.
|
255,934 | $9,861,137 |
All Filings in CELC
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $6,707,188 | 64,110 | Shares | Defined | 2026-08-13 | |
| No filing history on record for this holder in this stock. | ||||||